Association between plasma exosome neurogranin and brain structure in patients with Alzheimer's disease: a protocol study. Issue 8 (16th August 2020)

• Record Type: Journal Article
• Authors: He, MengFei; Sun, Li; Cao, Wenhui; Yin, Changhao; Sun, Wenqiang; Liu, Ping; Tan, Lin; Xu, Zheng; Zhao, Weina
• Is Part Of: BMJ open. Volume 10:Issue 8(2020)
• Publication Date: 2020-08-16
• Subjects: neurology -- neuroradiology -- radiology & imaging; Medicine -- Research -- Periodicals; 610.72
• DOI: 10.1136/bmjopen-2020-036990
• Languages: English
• ISSNs: 2044-6055

Abstract

Abstract : Introduction: Neurogranin is known to be significantly elevated in patients with Alzheimer's disease (AD) and may be an effective clinical predictor of cognitive decline and neurodegeneration. Amnestic mild cognitive impairment (aMCI) is an intermediate disease state between normal cognitive ageing and dementia, the latter of which can easily revert to AD. There remains significant uncertainty regarding the conversion of aMCI to AD, and therefore, elucidating such progression is paramount to the field of cognitive neuroscience. In this protocol study, we therefore aim to investigate the changes in plasma neurogranin in the early stage of AD and the mechanism thereof regarding the cognitive progression towards AD. Methods and analysis: In this study, patients with aMCI and AD patients (n=70 each) will be recruited at the memory clinic of the Department of Neurology of Hongqi Hospital affiliated with the Mudanjiang Medical University of China. Healthy older controls (n=70) will also be recruited from the community. All subjects will undergo neuroimaging and neuropsychological evaluations in addition to blood collection at the first year and the third year. We hope to identify a new biomarker of cognitive decline associated with AD and characterise its behaviour throughout the progression of aMCI to AD. This work will reveal novel targets for the therapeutic prevention, diagnosis and treatment of AD. The primary outcome measures will be (1) neuropsychological evaluation, including Mini-Mental State Examination, Montreal Cognitive Assessment, Clinical Dementia Rating scale, Shape Trail Test-A&B, Auditory Verbal Learning Test-HuaShan version; (2) microstructural alterations and hippocampal features from MRI scans; and (3) neurogranin levels in the neuronal-derived exosomes from peripheral blood samples. Ethics and dissemination: The ethics committee of the Hongqi Hospital affiliated with the Mudanjiang Medical University of China has approved this study protocol. The results will be published in peer-reviewed journals and presented at national or international scientific conferences. Trial registration number: ChiCTR2000029055.